Free
ISBT MEMBERS ONLY
Aim of the webinar:
The webinar will provide a state-of-the art update on recent laboratory studies and clinical trials of cryopreserved platelets, and how these might influence how they might be used in future.
Level of education required:
4 - Advanced (applied theory)
What knowledge is required?
Attendees should have an intermediate to advanced knowledge of platelet biology and function, and blood component storage.
Target audience
Scientists, blood bankers, transfusion practitioners, master or PhD students.
The Speakers
Denese Marks
Regional Director Western Pacific (2020-2024)
Denese Marks earned her PhD at the University of Technology, Sydney, followed by post-doctoral fellowships at the University of Vienna, the University of Melbourne and the Institute of Child Health at Great Ormond Street Hospital in London, as well as working in the biotechnology industry. Denese is the National Leader for Product Development at Australian Red Cross LifeBlood, where her research focuses on developing new blood products to meet patient needs, improving blood component processing and storage, platelet and red cell cryopreservation, pathogen inactivation and clinical trials of blood products. She is also an adjunct Associate Professor with the University of Sydney School of Medicine. Denese is a Section Editor for Vox Sanguinis, a scientific member of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative and a member of the Executive Committee for the ISBT Cellular Therapies Working Party.
Lacey Johnson
Dr Lacey Johnson is a Principal Research Fellow in the Product Development and Transfusion Studies Research team at Australian Red Cross Lifeblood and holds a Visiting Fellow position at the University of Technology Sydney. Dr Johnson is a cell biologist, with expertise in platelet biology, specifically platelet storage. She conducts fundamental, translational and clinical research aimed at improving the quality and safety of platelet products for transfusion. She has been involved in the conduct of two clinical trials of novel blood products developed through her research. Dr Johnson has over 60 publications and an extensive network of collaborators, nationally and internationally. She is also the secretary of the ISBT Blood Components Working Party.
Michael Reade
